Multicenter, Prospective, Non-randomized, Single-arm, Interventional Study for the Evaluation of the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse
- Conditions
- Anterior Vaginal Wall Prolapse With/Without Apical/Uterine Descent
- Interventions
- Device: SRS - Self Retaining Support system
- Registration Number
- NCT03195361
- Lead Sponsor
- Lyra Medical Ltd.
- Brief Summary
A prospective, single arm, multi-center clinical study to evaluate the safety and performance of the SRS (Lyra Medical) vaginal mesh in POP patients
- Detailed Description
The SRS implant is intended for transvaginal surgical treatment of anterior vaginal wall prolapse with or without vaginal apex/uterine prolapses
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 50
- Patient has signed the informed consent form and is willing to participate in the clinical study and data collection.
- Patient age is between 50 and 75 years old
- POP-Q: Aa and/or Ba is at least -1
- Patient is pregnant or breastfeeding
- Patient is suffering from active infection (on antibiotic therapy)
- Patient is planning vaginal delivery
- Patient had previous vaginal mesh surgery
- Patient is in high risk for surgery (evidence of clinically significant cardiovascular, renal, hepatic, coagulatory or respiratory diseases).
- Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.
- Malignancy.
- Known hypersensitivity to PEEK and/or polypropylene materials.
- Participation in another investigational trial that has not completed the primary endpoint or interferes with study participation.
- Diagnosed with mental or emotional disturbance.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single-arm SRS - Self Retaining Support system Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
- Primary Outcome Measures
Name Time Method No unexpected serious adverse device related events 36 months Improvement in POP-Q point C: 36 months Point C at -5 or less
Improvement in POP-Q points Aa and Ba 36 months Points Aa and\\or Ba are less than -1
- Secondary Outcome Measures
Name Time Method Achieving normal urinary function: 36 Months Patient does not experience voiding dysfunction and have negative Urinary Cough Test.
Improvement in Quality Of Life (QoL) 36 Months Subjective bother involving pelvic floor disorders using validated scales including PFDI-20 and PSIQ-12.
Trial Locations
- Locations (3)
Asaf HaRofeh Medical Center
🇮🇱Zrifin, Israel
Mayanei HaYeshua Medical Center
🇮🇱Bnei Brak, Israel
Ziv Medical center
🇮🇱Safed, Israel